Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x 24.6 35.7 69.0% View Chart
P/BV x 5.9 4.1 143.4% View Chart
Dividend Yield % 0.8 0.5 165.4%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-20
CIPLA
Mar-20
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs2,720586 464.6%   
Low Rs1,660357 465.3%   
Sales per share (Unadj.) Rs697.9207.0 337.1%  
Earnings per share (Unadj.) Rs96.118.6 516.9%  
Cash flow per share (Unadj.) Rs117.333.2 353.6%  
Dividends per share (Unadj.) Rs25.004.00 625.0%  
Dividend yield (eoy) %1.10.8 134.4%  
Book value per share (Unadj.) Rs515.2195.5 263.6%  
Shares outstanding (eoy) m119.57806.35 14.8%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x3.12.3 137.9%   
Avg P/E ratio x22.825.3 89.9%  
P/CF ratio (eoy) x18.714.2 131.5%  
Price / Book Value ratio x4.32.4 176.4%  
Dividend payout %26.021.5 120.9%   
Avg Mkt Cap Rs m261,879379,912 68.9%   
No. of employees `00014.325.8 55.4%   
Total wages/salary Rs m15,05530,270 49.7%   
Avg. sales/employee Rs Th5,822.66,459.6 90.1%   
Avg. wages/employee Rs Th1,050.51,171.2 89.7%   
Avg. net profit/employee Rs Th802.0580.2 138.2%   
INCOME DATA
Net Sales Rs m83,444166,949 50.0%  
Other income Rs m1,0423,442 30.3%   
Total revenues Rs m84,486170,391 49.6%   
Gross profit Rs m14,73432,060 46.0%  
Depreciation Rs m2,52811,747 21.5%   
Interest Rs m6511,974 33.0%   
Profit before tax Rs m12,59821,782 57.8%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,1056,312 17.5%   
Profit after tax Rs m11,49314,995 76.6%  
Gross profit margin %17.719.2 91.9%  
Effective tax rate %8.829.0 30.3%   
Net profit margin %13.89.0 153.3%  
BALANCE SHEET DATA
Current assets Rs m54,960117,038 47.0%   
Current liabilities Rs m32,43343,931 73.8%   
Net working cap to sales %27.043.8 61.7%  
Current ratio x1.72.7 63.6%  
Inventory Days Days8096 83.1%  
Debtors Days Days7285 84.8%  
Net fixed assets Rs m32,710107,424 30.4%   
Share capital Rs m2391,613 14.8%   
"Free" reserves Rs m61,368156,018 39.3%   
Net worth Rs m61,607157,630 39.1%   
Long term debt Rs m1,59223,693 6.7%   
Total assets Rs m99,433236,626 42.0%  
Interest coverage x20.412.0 169.2%   
Debt to equity ratio x00.2 17.2%  
Sales to assets ratio x0.80.7 118.9%   
Return on assets %12.27.2 170.3%  
Return on equity %18.79.5 196.1%  
Return on capital %21.012.8 163.3%  
Exports to sales %19.133.0 57.7%   
Imports to sales %3.00-   
Exports (fob) Rs m15,91755,175 28.8%   
Imports (cif) Rs m2,483NA-   
Fx inflow Rs m16,06156,036 28.7%   
Fx outflow Rs m2,4836,764 36.7%   
Net fx Rs m13,57849,272 27.6%   
CASH FLOW
From Operations Rs m5,85130,685 19.1%  
From Investments Rs m-7,4141,040 -712.6%  
From Financial Activity Rs m792-29,488 -2.7%  
Net Cashflow Rs m-7312,340 -31.2%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PANACEA BIOTECH  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 450 Points in Opening Trade; Mindtree Up 5% Post Q3 Results(09:30 am)

Asian share markets and US stock futures are trading higher today as investors awaited comments from Joe Biden's Treasury Secretary nominee Janet Yellen on US stimulus and the dollar.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Jan 19, 2021 11:24 AM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - CADILA HEALTHCARE COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS